2 Sizzling Hot Biotechnology Stocks: Celldex Therapeutics, Inc. (CLDX), CytRx Corporation (CYTR)
By Albert Farrington On March 23, 2016
Celldex Therapeutics, Inc. (CLDX) ended last trading session with a change of 7.76 percent. It trades at an average volume of 3.83M shares versus 4.94M shares recorded at the end of last trading session. The share price of $3.89 is at a distance of 31.42 percent from its 52-week low and down -87.25 percent versus its peak. The company has a market cap of $383.94M and currently has 98.70M shares outstanding. The share price is currently -26.12 percent versus its SMA20, -48 percent versus its SMA50, and -74.3 percent versus its SMA200. The stock has a weekly performance of 18.6 percent and is -75.19 percent year-to-date as of the recent close.
Celldex Therapeutics, Inc. (CLDX) on March 7, 2016 announced that the independent Data Safety and Monitoring Board (DSMB) has determined, based on a preplanned interim analysis, that continuation of the Phase 3 ACT IV study of RINTEGA® (rindopepimut) in patients with newly diagnosed EGFRvIII-positive glioblastoma will not reach statistical significance for overall survival in patients with minimal residual disease, the primary endpoint of the study, as both the RINTEGA arm and the control arm are performing on par with each other. In the ACT IV study, RINTEGA has performed consistently with prior Phase 2 studies but the control arm has significantly outperformed expectations (Hazard ratio = 0.99; median OS: RINTEGA 20.4 months vs. control 21.1 months). Based on this recommendation, Celldex is discontinuing the study and does not anticipate incurring substantial additional costs related to RINTEGA at this time. All patients on the RINTEGA arm of the ACT IV study, prior Phase 2 studies and existing compassionate use recipients will be offered ongoing access to RINTEGA on a compassionate use basis. Celldex first received the data after market close on Friday, March 4th and is in the process of reviewing the results.
Celldex currently has seven company-led clinical trials across five product candidates ongoing. The Company expects to report data from a number of these studies over the next three to 18 months, including a registration study in triple negative breast cancer and a number of Phase 1 and 2 cancer immunotherapy combination trials.
CytRx Corporation (CYTR) recently recorded 7.91 percent change and currently at $2.73 is 76.13 percent away from its 52-week low and down -49.63 percent versus its peak. It has a past 5-day performance of 34.48 percent and trades at an average volume of 592.45K shares. The stock has a 1-month performance of 0 percent and is 3.02 percent year-to-date as of the recent close. There were about 66.50M shares outstanding which made its market cap $181.55M. The share price is currently 8.08 percent versus its SMA20, 23.04 percent versus its SMA50, and -1.6 percent versus its SMA200.
CytRx Corporation (CYTR) on March 22, 2016 announced that it will present two posters with new preclinical data based on its proprietary LADR™ technology at the upcoming 2016 American Association of Cancer Research (AACR) Annual Meeting, April 16-20, 2016, being held at the Ernest N. Morial Convention Center in New Orleans, Louisiana.
Highlights include data on DK049, CytRx’s next albumin-binding drug conjugate nominated for clinical development, which demonstrated superior anti-tumor efficacy compared to gemcitabine in human patient-derived tumor xenograft models of non-small cell lung cancer, ovarian cancer and pancreatic cancer. DK049 decreases the clearance and drug resistance mechanisms that limit the effectiveness of gemcitabine, one of the most commonly used chemotherapy drugs. As a result, DK049’s superior anti-tumor efficacy was achieved using a significantly reduced dose compared to gemcitabine. CytRx plans to commence clinical trials with DK049 in the second half of this year.
CytRx’s second poster details the broad capabilities of the Company’s LADRTM (Linker Activated Drug Release) technology platform. A key advantage is a suite of versatile linkers with the ability to control the release profile of potent cytotoxic agents between 1-50 hours to create personalized therapies for specific cancers. DK049 and the LADRTM technology platform were created in-house at CytRx’s drug discovery lab in Freiburg, Germany.
By Albert Farrington On March 23, 2016
Celldex Therapeutics, Inc. (CLDX) ended last trading session with a change of 7.76 percent. It trades at an average volume of 3.83M shares versus 4.94M shares recorded at the end of last trading session. The share price of $3.89 is at a distance of 31.42 percent from its 52-week low and down -87.25 percent versus its peak. The company has a market cap of $383.94M and currently has 98.70M shares outstanding. The share price is currently -26.12 percent versus its SMA20, -48 percent versus its SMA50, and -74.3 percent versus its SMA200. The stock has a weekly performance of 18.6 percent and is -75.19 percent year-to-date as of the recent close.
Celldex Therapeutics, Inc. (CLDX) on March 7, 2016 announced that the independent Data Safety and Monitoring Board (DSMB) has determined, based on a preplanned interim analysis, that continuation of the Phase 3 ACT IV study of RINTEGA® (rindopepimut) in patients with newly diagnosed EGFRvIII-positive glioblastoma will not reach statistical significance for overall survival in patients with minimal residual disease, the primary endpoint of the study, as both the RINTEGA arm and the control arm are performing on par with each other. In the ACT IV study, RINTEGA has performed consistently with prior Phase 2 studies but the control arm has significantly outperformed expectations (Hazard ratio = 0.99; median OS: RINTEGA 20.4 months vs. control 21.1 months). Based on this recommendation, Celldex is discontinuing the study and does not anticipate incurring substantial additional costs related to RINTEGA at this time. All patients on the RINTEGA arm of the ACT IV study, prior Phase 2 studies and existing compassionate use recipients will be offered ongoing access to RINTEGA on a compassionate use basis. Celldex first received the data after market close on Friday, March 4th and is in the process of reviewing the results.
Celldex currently has seven company-led clinical trials across five product candidates ongoing. The Company expects to report data from a number of these studies over the next three to 18 months, including a registration study in triple negative breast cancer and a number of Phase 1 and 2 cancer immunotherapy combination trials.
CytRx Corporation (CYTR) recently recorded 7.91 percent change and currently at $2.73 is 76.13 percent away from its 52-week low and down -49.63 percent versus its peak. It has a past 5-day performance of 34.48 percent and trades at an average volume of 592.45K shares. The stock has a 1-month performance of 0 percent and is 3.02 percent year-to-date as of the recent close. There were about 66.50M shares outstanding which made its market cap $181.55M. The share price is currently 8.08 percent versus its SMA20, 23.04 percent versus its SMA50, and -1.6 percent versus its SMA200.
CytRx Corporation (CYTR) on March 22, 2016 announced that it will present two posters with new preclinical data based on its proprietary LADR™ technology at the upcoming 2016 American Association of Cancer Research (AACR) Annual Meeting, April 16-20, 2016, being held at the Ernest N. Morial Convention Center in New Orleans, Louisiana.
Highlights include data on DK049, CytRx’s next albumin-binding drug conjugate nominated for clinical development, which demonstrated superior anti-tumor efficacy compared to gemcitabine in human patient-derived tumor xenograft models of non-small cell lung cancer, ovarian cancer and pancreatic cancer. DK049 decreases the clearance and drug resistance mechanisms that limit the effectiveness of gemcitabine, one of the most commonly used chemotherapy drugs. As a result, DK049’s superior anti-tumor efficacy was achieved using a significantly reduced dose compared to gemcitabine. CytRx plans to commence clinical trials with DK049 in the second half of this year.
CytRx’s second poster details the broad capabilities of the Company’s LADRTM (Linker Activated Drug Release) technology platform. A key advantage is a suite of versatile linkers with the ability to control the release profile of potent cytotoxic agents between 1-50 hours to create personalized therapies for specific cancers. DK049 and the LADRTM technology platform were created in-house at CytRx’s drug discovery lab in Freiburg, Germany.
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
